PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28577693
OWN - NLM
STAT- MEDLINE
DA  - 20170604
DCOM- 20170629
LR  - 20170629
IS  - 1524-4733 (Electronic)
IS  - 1098-3015 (Linking)
VI  - 20
IP  - 6
DP  - 2017 Jun
TI  - Economic Consequences and Potentially Preventable Costs Related to Osteoporosis
      in the Netherlands.
PG  - 762-768
LID - S1098-3015(17)30118-3 [pii]
LID - 10.1016/j.jval.2017.02.006 [doi]
AB  - BACKGROUND: Osteoporosis often does not involve symptoms, and so the actual
      number of patients with osteoporosis is higher than the number of diagnosed
      individuals. This underdiagnosis results in a treatment gap. OBJECTIVES: To
      estimate the total health care resource use and costs related to osteoporosis in 
      the Netherlands, explicitly including fractures, and to estimate the proportion
      of fracture costs that are linked to the treatment gap and might therefore be
      potentially preventable; to also formulate, on the basis of these findings,
      strategies to optimize osteoporosis care and treatment and reduce its related
      costs. METHODS: In this retrospective study, data of the Achmea Health Database
      representing 4.2 million Dutch inhabitants were used to investigate the economic 
      consequence of osteoporosis in the Netherlands in 2010. Specific cohorts were
      created to identify osteoporosis-related fractures and their costs. Besides,
      costs of pharmaceutical treatment regarding osteoporosis were included. Using
      data from the literature, the treatment gap was estimated. Sensitivity analysis
      was performed on the base-case results. RESULTS: A total of 108,013 individuals
      with a history of fractures were included in this study. In this population,
      59,193 patients were using anti-osteoporotic medication and 86,776 patients were 
      using preventive supplements. A total number of 3,039 osteoporosis-related
      fractures occurred. The estimated total costs were euro465 million. On the basis 
      of data presented in the literature, the treatment gap in our study population
      was estimated to vary from 60% to 72%. CONCLUSIONS: The estimated total costs
      corrected for treatment gap were euro1.15 to euro1.64 billion. These results
      indicate room for improvement in the health care policy against osteoporosis.
CI  - Copyright (c) 2017 International Society for Pharmacoeconomics and Outcomes
      Research (ISPOR). Published by Elsevier Inc. All rights reserved.
FAU - Dunnewind, Tom
AU  - Dunnewind T
AD  - Unit of PharmacoTherapy, -Epidemiology and -Economics (PTE2), Department of
      Pharmacy, University of Groningen, Groningen, The Netherlands. Electronic
      address: [email protected]
FAU - Dvortsin, Evgeni P
AU  - Dvortsin EP
AD  - Unit of PharmacoTherapy, -Epidemiology and -Economics (PTE2), Department of
      Pharmacy, University of Groningen, Groningen, The Netherlands; Asc Academics
      B.V., Groningen, The Netherlands.
FAU - Smeets, Hugo M
AU  - Smeets HM
AD  - Achmea Health Care Insurance N.V., Leusden, The Netherlands.
FAU - Konijn, Rob M
AU  - Konijn RM
AD  - Achmea Health Care Insurance N.V., Leusden, The Netherlands.
FAU - Bos, Jens H J
AU  - Bos JHJ
AD  - Unit of PharmacoTherapy, -Epidemiology and -Economics (PTE2), Department of
      Pharmacy, University of Groningen, Groningen, The Netherlands.
FAU - de Boer, Pieter T
AU  - de Boer PT
AD  - Unit of PharmacoTherapy, -Epidemiology and -Economics (PTE2), Department of
      Pharmacy, University of Groningen, Groningen, The Netherlands.
FAU - van den Bergh, Joop P
AU  - van den Bergh JP
AD  - Department of Internal Medicine, Viecuri Medical Center, Venlo, The Netherlands; 
      Department of Internal Medicine, University Medical Center Maastricht,
      Maastricht, The Netherlands; Faculty of Medicine and Life Sciences, University of
      Hasselt, Diepenbeek, Belgium.
FAU - Postma, Maarten J
AU  - Postma MJ
AD  - Unit of PharmacoTherapy, -Epidemiology and -Economics (PTE2), Department of
      Pharmacy, University of Groningen, Groningen, The Netherlands; Institute of
      Science in Healthy Aging & healthcaRE (SHARE), University Medical Center
      Groningen, University of Groningen, Groningen, The Netherlands; Department of
      Epidemiology, University Medical Center Groningen, University of Groningen,
      Groningen, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170327
PL  - United States
TA  - Value Health
JT  - Value in health : the journal of the International Society for Pharmacoeconomics 
      and Outcomes Research
JID - 100883818
RN  - 0 (Bone Density Conservation Agents)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Bone Density Conservation Agents/*administration & dosage/economics
MH  - Databases, Factual
MH  - Dietary Supplements/*economics
MH  - Female
MH  - *Health Care Costs
MH  - Health Policy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Netherlands
MH  - Osteoporosis/diagnosis/*economics/therapy
MH  - Osteoporotic Fractures/*economics/prevention & control
MH  - Retrospective Studies
OTO - NOTNLM
OT  - costs analysis
OT  - osteoporosis
OT  - osteoporotic fractures
OT  - the Netherlands
EDAT- 2017/06/05 06:00
MHDA- 2017/07/01 06:00
CRDT- 2017/06/05 06:00
PHST- 2016/10/12 [received]
PHST- 2017/02/01 [revised]
PHST- 2017/02/08 [accepted]
AID - S1098-3015(17)30118-3 [pii]
AID - 10.1016/j.jval.2017.02.006 [doi]
PST - ppublish
SO  - Value Health. 2017 Jun;20(6):762-768. doi: 10.1016/j.jval.2017.02.006. Epub 2017 
      Mar 27.